ASCO Education
ASCO Education: By the Book features engaging discussions between editors and authors from the ASCO Educational Book. Hear nuanced views on topics featured in Education Sessions at ASCO meetings and deep dives on the approaches shaping modern oncology that have care teams talking.
Latest episodes
Jun 6, 2018 • 5min
Self-Evaluation: EGFR Mutation
Self-Evaluation: Apar Kishor Ganti, MD, Professor in the Department of Internal Medicine, Division of Oncology/Hematology, and Associate Director of Clinical Research at the Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, presents a self-evaluation question from an ASCO University course focusing on the treatment of an EGFR Mutation.
May 30, 2018 • 5min
Recently Approved Drugs: Olaparib for germline BRCA-mutated metastatic breast cancer
Dr. Linh Alejandro, a clinical oncology pharmacist at the University of California, San Diego Health Systems discusses the approval of olaparib for germline BRCA-mutated metastatic breast cancer.
May 23, 2018 • 11min
ASCO Guidelines: Outpatient Management of Fever and Neutropenia
An interview with Dr. Christopher Flowers of Emory University School of Medicine on the ASCO/IDSA clinical practice guideline which provides updated recommendations on outpatient management of fever and neutropenia in patients with cancer. Read the full guideline at www.asco.org/supportive-care-guidelines
May 16, 2018 • 6min
Self-Evaluation: NSCLC Treatment Metastatic
Shadia Jalal, MD, Assistant Professor of Clinical Medicine Department of Medicine Division of Hematology/Oncology Indiana University School of Medicine, presents a self-evaluation question from an ASCO University course focusing on the treatment of non-small cell lung cancers.
May 9, 2018 • 7min
Adjuvant Treatment in Melanoma: Recent Advances
Dr. Rodrigo Munhoz, medical oncologist at Centro de Oncologia- Hospital Sírio-Libanês in Sao Paolo, Brazil, discusses recent advances in the adjuvant therapy for patients with high-risk melanoma
May 2, 2018 • 5min
Recently Approved Drugs: Blinatumomab for B-cell precursor ALL
Alex Ganetsky, PharmD, BCOP, oncology clinical pharmacy specialist at the Hospital of the University of Pennsylvania in Philadelphia discusses the approval to blinatumomab (Blincyto, Amgen Inc.) for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.
Apr 25, 2018 • 16min
Guidelines: Management of Immune-Related Adverse Events
An interview with Dr. Bryan Schneider of the University of Michigan on the ASCO clinical practice guideline to increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICPi) therapy. Read the full guideline at www.asco.org/supportive-care-guidelines
Apr 18, 2018 • 8min
Treatment Effects & Transition to Survivorship for AYA Patients
Cindy Schwartz, MD, MPH, is an accomplished oncologist who brings 35 years of experience, passion and expertise in the areas of Hodgkin lymphoma, osteosarcoma and childhood cancer survivorship.
Apr 11, 2018 • 6min
EHR Chemotherapy Error: Breast Cancer
Dr. Carolyn Hendricks is a board certified medical oncologist specializing in breast cancer. She received her medical degree from Johns Hopkins University School of Medicine and has been in practice for more than 20 years.
Apr 4, 2018 • 5min
Continuity of Care for AYAs
Dr. Larissa Nekhlyudov is a board-certified general internist and Medical Director of Primary Care Associates, Longwood. Dr. Nekhlyudov practiced internal medicine at Harvard Vanguard Medical Associates for over 15 years. In this episode she discusses the importance of effective communication between the primary care physician & oncologist for AYA patients diagnosed with cancer.
